Recognizing the growing and significant role in delivering precision medicine to patients, the 2018 SNMMI Mid-Winter and ACNM Annual Meeting, taking place January 25-27, 2018 in Orlando, Florida, will feature a dedicated track on Theranostics.
SNMMI offers a number of free resources on the Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study, including helpful links and on-demand webinars.
The new technologies of radionuclide therapy are allowing for personalized treatment of various forms of cancer. Learn more about the clinical utility of these procedures and earn free CE credit.
Welcome to our Healthcare Provider portal. Everything you need to understand the advantages and applications of nuclear medicine and molecular imaging in your practice. Find out more about ordering the right test for the right patient at the right time.
Appropriate Use Criteria (AUC) are statements that contain indications describing when, and how often, an intervention should be performed under the auspices of scientific evidence, clinical judgment, and patient values while avoiding unnecessary provisions of services. SNMMI follows a balanced multidisciplinary approach to guidance development by including various stakeholders in the development process. To view the development process, please click the following link: SNMMI AUC Development Process.
SNMMI has created guidelines to identify those elements of the procedure that are most important in obtaining a high-quality examination, Appropriate Use Criteria (AUC), and is working towards optimizing dose.
The SNMMI PET Center of Excellence has created a go-to resource with in-depth ordering information and printable materials related to PET and PET/CT, including:
SNMMI is dedicated to providing the community with access to the most knowledgeable and experienced speakers in the field of nuclear medicine and molecular imaging. As part of the new Outreach Program, SNMMI is working to enhance relationships with relevant societies and patient organizations. We have created a pool of speakers who can speak at your next meeting. Please complete the form below to request a speaker.
Dopamine transporter (DaT) imaging, with single-photon emission computed tomography (SPECT), is used to diagnose Parkinson’s disease. To help patients who are scheduled for a DaT SPECT procedure, SNMMI’s Brain Imaging Outreach Working Group created a video that takes the patient through what happens at each step.
On March 30, 2018, Aetna issued a revised PET coverage policy that failed to cover Dotatate and Fluciclovine. SNMMI requests that it change these policies.
(Government Relations News)
SNMMI and the Education and Research Foundation for Nuclear Medicine and Molecular Imaging are pleased to announce that Aria Razmaria, MD, has been selected as the recipient of the 2018 Robert E. Henkin Government Relations Fellowship.
(Government Relations News)
A PET imaging agent could show, ahead of time, whether a specific treatment is likely to be effective for major depressive disorder—a debilitating condition that affects more than 14 million Americans. No such marker is currently available in clinical psychiatry. The study is featured in the April issue of The Journal of Nuclear Medicine.
Happy Nuclear Medicine Week! Encourage community members to take pride in their profession – recognizing their colleagues for their hard work and promoting nuclear medicine to the entire medical community as well as to the public.
SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis. Most of this information is in the government relations news section of this web site.
Learn more about journals published by or sponsored by the Society of Nuclear Medicine and Molecular Imaging.
Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.